Biotech | March 11, 2022
Emmes acquires Casimir, its fourth major acquisition
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
A simple blood test detects over 30 types of cancers
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)